Literature DB >> 16928889

Serum antibodies to pneumococcal neuraminidase NanA in relation to pneumococcal carriage and acute otitis media.

Birgit Simell1, Teija Jaakkola, Mika Lahdenkari, David Briles, Susan Hollingshead, Terhi M Kilpi, Helena Käyhty.   

Abstract

Pneumococcal neuraminidase, NanA, is a pneumococcal vaccine candidate. Prior culture-confirmed pneumococcal contacts were shown to induce serum anti-NanA antibodies during the first 2 years of life. The antibody concentrations at neither 12 nor 18 months were significantly associated with the risk of subsequent pneumococcal carriage or acute otitis media.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16928889      PMCID： PMC1595316          DOI： 10.1128/CVI.00257-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  26 in total

1.  Evaluation of the virulence of a Streptococcus pneumoniae neuraminidase-deficient mutant in nasopharyngeal colonization and development of otitis media in the chinchilla model.

Authors:  H H Tong; L E Blue; M A James; T F DeMaria
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

2.  Nasopharyngeal carriage of Streptococcus pneumoniae in Finnish children younger than 2 years old.

Authors:  R K Syrjänen; T M Kilpi; T H Kaijalainen; E E Herva; A K Takala
Journal:  J Infect Dis       Date:  2001-07-06       Impact factor: 5.226

3.  Bacteriology of acute otitis media in a cohort of Finnish children followed for the first two years of life.

Authors:  T Kilpi; E Herva; T Kaijalainen; R Syrjänen; A K Takala
Journal:  Pediatr Infect Dis J       Date:  2001-07       Impact factor: 2.129

4.  Antibodies to conserved pneumococcal antigens correlate with, but are not required for, protection against pneumococcal colonization induced by prior exposure in a mouse model.

Authors:  Krzysztof Trzcinski; Claudette Thompson; Richard Malley; Marc Lipsitch
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

5.  Comparison of structural changes of cell surface carbohydrates in the eustachian tube epithelium of chinchillas infected with a Streptococcus pneumoniae neuraminidase-deficient mutant or its isogenic parent strain.

Authors:  H H Tong; M James; I Grants; X Liu; G Shi; T F DeMaria
Journal:  Microb Pathog       Date:  2001-12       Impact factor: 3.738

6.  Neuraminidase expressed by Streptococcus pneumoniae desialylates the lipopolysaccharide of Neisseria meningitidis and Haemophilus influenzae: a paradigm for interbacterial competition among pathogens of the human respiratory tract.

Authors:  Elizabeth A Shakhnovich; Samantha J King; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

7.  Changes in availability of oxygen accentuate differences in capsular polysaccharide expression by phenotypic variants and clinical isolates of Streptococcus pneumoniae.

Authors:  J N Weiser; D Bae; H Epino; S B Gordon; M Kapoor; L A Zenewicz; M Shchepetov
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

8.  Anti-PsaA and the risk of pneumococcal AOM and carriage.

Authors:  Satu Rapola; Virva Jäntti; Mervi Eerola; P Helena Mäkelä; Helena Käyhty; Terhi Kilpi
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

9.  Immunization with native or recombinant Streptococcus pneumoniae neuraminidase affords protection in the chinchilla otitis media model.

Authors:  J P Long; H H Tong; T F DeMaria
Journal:  Infect Immun       Date:  2004-07       Impact factor: 3.441

10.  The immune response to pneumococcal proteins during experimental human carriage.

Authors:  Tera L McCool; Thomas R Cate; Gregory Moy; Jeffrey N Weiser
Journal:  J Exp Med       Date:  2002-02-04       Impact factor: 14.307
View more
  6 in total

1.  Natural antibodies against several pneumococcal virulence proteins in children during the pre-pneumococcal-vaccine era: the generation R study.

Authors:  Ankie Lebon; Nelianne J Verkaik; Joost A M Labout; Corné P de Vogel; Herbert Hooijkaas; Henri A Verbrugh; Willem J B van Wamel; Vincent W V Jaddoe; Albert Hofman; Peter W M Hermans; Jiangtao Ma; Tim J Mitchell; Henriette A Moll; Alex van Belkum
Journal:  Infect Immun       Date:  2011-01-31       Impact factor: 3.441

2.  Influence of age, social patterns and nasopharyngeal carriage on antibodies to three conserved pneumococcal surface proteins (PhtD, PcpA and PrtA) in healthy young children.

Authors:  A Hagerman; K M Posfay-Barbe; S Grillet; M M Ochs; R H Brookes; D Greenberg; N Givon-Lavi; R Dagan; C-A Siegrist
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-08-18       Impact factor: 3.267

3.  Antibodies to pneumococcal proteins PhtD, CbpA, and LytC in Filipino pregnant women and their infants in relation to pneumococcal carriage.

Authors:  Emma Holmlund; Beatriz Quiambao; Jukka Ollgren; Teija Jaakkola; Cécile Neyt; Jan Poolman; Hanna Nohynek; Helena Käyhty
Journal:  Clin Vaccine Immunol       Date:  2009-04-29

4.  Development of antibodies to PspA families 1 and 2 in children after exposure to Streptococcus pneumoniae.

Authors:  Merit M Melin; Susan K Hollingshead; David E Briles; Mika I Lahdenkari; Terhi M Kilpi; Helena M Käyhty
Journal:  Clin Vaccine Immunol       Date:  2008-08-27

5.  Interleukin-17A mediates acquired immunity to pneumococcal colonization.

Authors:  Ying-Jie Lu; Jane Gross; Debby Bogaert; Adam Finn; Linda Bagrade; Qibo Zhang; Jay K Kolls; Amit Srivastava; Anna Lundgren; Sophie Forte; Claudette M Thompson; Kathleen F Harney; Porter W Anderson; Marc Lipsitch; Richard Malley
Journal:  PLoS Pathog       Date:  2008-09-19       Impact factor: 6.823

6.  Assessing the function of pneumococcal neuraminidases NanA, NanB and NanC in in vitro and in vivo lung infection models using monoclonal antibodies.

Authors:  Philipp Janesch; Harald Rouha; Adriana Badarau; Lukas Stulik; Irina Mirkina; Marisa Caccamo; Katharina Havlicek; Barbara Maierhofer; Susanne Weber; Karin Groß; Jacqueline Steinhäuser; Manuel Zerbs; Cecilia Varga; Ivana Dolezilkova; Sabine Maier; Gerhild Zauner; Nels Nielson; Christine A Power; Eszter Nagy
Journal:  Virulence       Date:  2018       Impact factor: 5.882
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.